Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Dev Regulatory News (FDEV)

Share Price Information for Frontier Dev (FDEV)

Share Price is delayed by 15 minutes
Get Live Data
464.50    3.00 (0.65%)
Bid:
462.50
Ask:
465.50
Spread: 3.00 (0.649%)
Market Cap: £161.34m
FDEV Live PriceLast checked at - London Stock Exchange

Intraday Frontier Dev Share Chart

Proposed PCA Dealing

26 Nov 2019 16:59

RNS Number : 7546U
Frontier Developments PLC
26 November 2019
 

26 November 2019

Not for publication, distribution or release, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or Republic of South Africa or any other jurisdiction in which such release, publication or distribution would be unlawful.

Please see the Important Notice at the end of this announcement.

Frontier Developments plc

("Frontier" or the "Company")

Proposed PCA Dealing

Frontier Developments plc (AIM: FDEV) today announces that it has been notified by Wendy Irvin-Braben (the "Selling Shareholder") of her intention to sell up to 1,250,000 ordinary shares of 0.5 pence each in the Company ("Sale Shares"), in response to investor demand, at a price of 1,200 pence per Sale Share (the "Sale"). The Selling Shareholder is the wife of, and therefore a person closely associated with, the chief executive officer of the Company, David Braben.

The Sale Shares represent approximately 3.2% of the Company's issued share capital. Assuming all the Sale Shares are sold, the Selling Shareholder will, following completion of the Sale, continue to hold 1.9% of the issued share capital of the Company. Therefore, including Wendy Irvin-Braben's residual shareholding, David Braben will have a total interest of 12,899,953 ordinary shares or 33.2% of the issued share capital of the Company following the Sale.

The Selling Shareholder and David Braben have undertaken that, without the prior written consent of Jefferies International Limited and Liberum Capital Limited, they will not dispose of any further Ordinary Shares for a period of 360 days after completion of the Sale (subject to customary exceptions).

The Company is not a party to the Sale and will not receive any proceeds from the Sale.

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation (EU) 596/2014. The person responsible for making this announcement on behalf of the Company is Alex Bevis.

Enquiries:

 

Frontier Developments +44 (0)1223 394 300

David Braben, CEO

Alex Bevis, CFO

Liberum - Nomad and Joint Broker +44 (0)20 3100 2000

Neil Patel / Cameron Duncan

Jefferies - Joint Broker +44 (0)20 7029 8000

Max Jones / William Brown

Tulchan Communications +44 (0)20 7353 4200

Matt Low / Deborah Roney / James Macey White 

 

About Frontier Developments plc

Frontier is a leading independent creator of self-published videogame franchises founded in 1994 by David Braben, co-author of the iconic Elite game. Based in Cambridge, Frontier uses its proprietary 'COBRA' game development technology to create innovative games, currently focusing on videogame consoles and personal computers.

Frontier's LEI number: 213800B9LGPWUAZ9GX18.

www.frontier.co.uk 

IMPORTANT NOTICE

In connection with the Sale, Jefferies International Limited ("Jefferies") and Liberum Capital Limited ("Liberum" and, together with Jefferies, the "Managers") or any of their respective affiliates may take up a portion of the Sale Shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for its own accounts such Sale Shares and other securities of Frontier Developments plc or related investments in connection with the Sale or otherwise. Accordingly, references to the Sale Shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by either of the Managers and any of their respective affiliates acting as investors for their own accounts. The Managers do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Jefferies and Liberum are each authorised and regulated by the FCA. Each of the Managers is acting for the Seller only in connection with the Sale and no one else, and will not be responsible to anyone other than the Seller for providing the protections offered to clients of the Managers nor for providing advice in relation to the Sale Shares or the Sale, the contents of this announcement or any transaction, arrangement or other matter referred to in this announcement.

This announcement has been issued by the Company on behalf of the Seller and is the sole responsibility of the Seller apart from the responsibilities and liabilities, if any, that may be imposed on Jefferies or Liberum by the Financial Services and Markets Act 2000. Neither Jefferies nor Liberum accepts any responsibility whatsoever and makes no representation or warranty, express or implied, for the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by the Seller or on the Seller's behalf or on Jefferies' or Liberum's behalf, in connection with the Seller or the Sale, and nothing in this announcement is or shall be relied upon as a promise or representation in this respect, whether as to the past or the future. Each of Jefferies and Liberum accordingly disclaims to the fullest extent permitted by law all and any responsibility and liability, whether arising in tort, contract or otherwise, which it might otherwise have in respect of this announcement and any such statement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBLBDBRUDBGCL
Date   Source Headline
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSDirector/PDMR Shareholding
13th Mar 20267:00 amRNSDirector/PDMR Shareholding
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSDirector/PDMR Shareholding
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSDirector/PDMR Shareholding
11th Mar 20267:00 amRNSDirector/PDMR Shareholding
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSDirector/PDMR Shareholding
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSDirector/PDMR Shareholding
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSLaunch of on-market Share Buyback Programme
26th Feb 20267:00 amRNSBlock Listing Return
11th Feb 202610:45 amRNSOption Grants / PDMR Dealings
27th Jan 20263:43 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSExcellent H1 Results & full year outlook upgraded
2nd Jan 20267:00 amRNSAppointment of Chief Executive Officer
2nd Jan 20267:00 amRNSAppointment of Chief Executive Officer
16th Dec 20257:00 amRNSCEO TRANSITION
14th Nov 20251:37 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSA STRONG LAUNCH FOR JWE3 & A SEQUEL FOR PLANET ZOO
5th Nov 20258:57 amRNSHolding(s) in Company
29th Oct 202510:48 amRNSResult of AGM
21st Oct 20253:00 pmRNS-RJURASSIC WORLD EVOLUTION 3 IS OUT NOW!

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.